<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has submitted an initial disclosure to BSE under SEBI's Large Corporate Framework for FY 2025-26. The company has confirmed that as of 31st March 2025, it does not fall under the 'Large Corporate' category as defined by SEBI. Consequently, the company is not required to file the detailed annual or half-yearly disclosures mandated under the framework for the current financial year. The letter is signed by Whole-time Director Venkateshwarlu Pulluru and follows SEBI circulars dated October 19, 2023, August 10, 2021, and November 26, 2018.
This is a routine compliance filing with no material impact on shareholders or the stock. It simply confirms the company is below the Large Corporate threshold, meaning no additional incremental borrowing or ESG disclosures are required from it this year.